Lapatinib and trastuzumab shrinks HER2+ breast cancers within 11 days
11 March 2016 | By Victoria White
A trial has shown that lapatinib plus trastuzumab before surgery shrinks and may even destroy tumours in women with HER2+ breast cancer within 11 days. The EPHOS B trial studied 257 women with HER2 positive breast cancer in the short gap between initial diagnosis and surgery to remove their tumours.…